1 year ago

3 - color Key Fob (Crown Knot)

3-Color Crown Knot is easy to master in a few steps and the finished product is very pleasing to the eye. As many viewer can see I usually use the same colors because it is easier to see the guide in bright colors.

This type of knot is like read more...

2 years ago

Should I Store Wheat Berries or Flour

If you really want to start an argument online, ask the question What is better to store, Wheat berries or Flour? Within moments you should get a barrage of different arguments for both sides of the question. Simply, the correct answer is.. Whatev read more...

2 years ago

Tying the Unique Solomon Grenade

All data and information provided on this blog is for informational purposes only. The creator of this blog (Chad Poole a.k.a. SyberProdigy) makes no representations as to accuracy, completeness, currentness, suitability, or validity of any inform read more...

2 years ago

Utah's 'mountain man' survivalist sentenced to prison after guilty pleas | Reuters

SALT LAKE CITY A Utah survivalist known as the "mountain man" who evaded police for nearly six years while looting remote cabins for weapons and supplies was sentenced on Monday to more than 10 years in prison after pleading guilty to multiple sta read more...

2 years ago

Research and Markets: Global and Chinese Off-Grid Solar System Industry Report 2014-2019

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3lzcc2/global_and) has announced the addition of the "Global and Chinese Off-Grid Solar System Industry, 2009-2019" report to their offerin read more...

2 years ago

LEAVE _________ ALONE! | Answerbag

Leave people who deserve to be left alone alone.

Comments Add a comment...

read more...

2 years ago

Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamou

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in an open read more...